Menu
Search
|

Menu

Close
X

Foamix Pharmaceuticals Ltd FOMX.OQ (NASDAQ Stock Exchange Global Market)

6.22 USD
+0.10 (+1.63%)
As of Feb 24
chart
Previous Close 6.12
Open 6.15
Volume 18,415
3m Avg Volume 28,096
Today’s High 6.29
Today’s Low 6.07
52 Week High 10.20
52 Week Low 4.03
Shares Outstanding (mil) 37.43
Market Capitalization (mil) 241.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
2
FY16
6
FY15
1
EPS (USD)
FY17
-0.825
FY16
-0.896
FY15
-0.604
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
41.95
5.77
Price to Book (MRQ)
vs sector
2.39
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-49.58
14.43
Return on Equity (TTM)
vs sector
-49.79
16.13

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2 Holzman Street, Weizmann-Scien
REHOVOT     76704

Phone: +9728.9316233

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

SPONSORED STORIES